BIX 2026 Counts Down To Opening With Post-GLP-1 Session On The Next Obesity Treatment Market
With one month to go before the opening, BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026) has released its full conference schedule,“Conference At a Glance.” BIX 2026, Korea's largest biotechnology and pharmaceutical convention, will be held at COEX in Seoul from October 28 to 30. The event will bring together more than 300 companies from around the world and more than 90 speakers from Korea and abroad to discuss key technologies and market issues shaping the bioindustry.
This year's conference will broadly examine recent changes across the industry, from next-generation drug development technologies and investment and M&A to regulatory issues, global expansion, and new businesses built around biotechnology. Key topics will include AI-driven drug development, radiopharmaceuticals (RPT), and NewCo models, as well as emerging areas such as preventive nutrition, connected care, space biotech, animal health, and beauty.
Among these topics, the Post-GLP-1 session will examine the next generation of the obesity treatment market. Competition among next-generation obesity treatment pipelines has intensified following the commercial success of GLP-1 therapies. As follow-on treatment development accelerates, pricing and patient access, reliable manufacturing and supply capabilities, and partnerships with global pharmaceutical companies are emerging as key factors that could shape the market.
BIX 2026 will address this landscape through a dedicated conference session titled“ Post-GLP-1: Who Will Lead the Next Expansion of the Obesity Market?” The session will bring together industry leaders to discuss investment, development, and global competitive strategies in the Post-GLP-1 market. Speakers include:
Billy Cho, PE and Head of JVC, CBC Group
Huizhong Xiong, Vice President of Innovent Biologics
Inyoung Choi, PhD, Senior Executive Vice President and Head of R&D Division of Hanmi Pharmaceutical
Seulki Lee, CEO of D&D Pharmatech
Cho will address the obesity treatment sector from a global investor's perspective, how therapeutic efficacy, pricing, patient access, and supply capacity influence covering investment decisions, as well as recent investment and dealmaking trends in the sector. Xiong will draw on Innovent Biologics' experience partnering with multiple global pharmaceutical companies to discuss strategies for Chinese biotech companies entering global markets and advancing obesity and metabolic disease pipelines internationally.
Choi will offer the perspective of a Korean pharmaceutical company, discussing differentiation strategies, partnering, and drug pricing and access issues in the global obesity treatment market. Lee will outline the direction of next-generation drug development, focusing on novel mechanisms such as multi-agonists and unmet needs in the current GLP-1 treatment landscape.
“The bioindustry's business strategies are evolving rapidly as next-generation therapeutics,
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment